Abstract
Since the advent of prostate-specific antigen (PSA) testing, the incidence of prostate cancer has risen sharply, and the consensus has been that many patients with low-risk disease are being overtreated. Yet during the PSA era, disease-specific mortality has remained relatively stable, though data regarding outcomes for prostate cancer patients are lacking. Now, to assess the causes of death among a modern cohort of men with prostate cancer, investigators used data from population-based databases from the U.S. and Sweden, two countries with some of the highest incidence rates of …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
